NCT02988726View on ClinicalTrials.gov

Antineoplaston Therapy in Treating Patients With Neurofibroma and Schwannoma

PHASE2TerminatedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

March 31, 1999

Primary Completion Date

August 31, 2001

Study Completion Date

August 31, 2001

Conditions
CNS Tumor
Interventions
DRUG

Antineoplaston therapy (Atengenal + Astugenal)

Adults with a recurrent/residual Neurofibroma or Schwannoma will receive Antineoplaston therapy (Atengenal + Astugenal).

Trial Locations (1)

77055-6330

Burzynski Clinic, Houston

Sponsors
All Listed Sponsors
lead

Burzynski Research Institute

OTHER